Fermion is happy to announce that we have received Certificate of Suitability (CEP) for Benserazide Hydrochloride issued in July 2023, and for Entacapone issued in June 2023. For Entacapone Drug Master File (DMF) is also available in USA.

Both mentioned active pharmaceutical ingredients are used for treatment of Parkinson’s disease together with Levodopa. Benserazide prevents metabolism of Levodopa into dopamine in blood circulation outside brain tissues thus boosting Levodopa accumulation into brain. Simultaneously negative side impact of peripheral dopamine are minimized. Entacapone, in similar manner, is boosting effectiveness of levodopa by decreasing its metabolism pace.

More information regarding the quality and availability of Benserazide HCl and Entacapone and can be requested from your sales contact.